^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | gemcitabine (DNA synthesis inhibitor) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Resistant |
Evidence:
Source:
Title:
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
Published date:
05/25/2023
Excerpt:
In patients with advanced PDAC and a G12C mutation, median overall survival appears significantly longer in those treated with GP compared to FOLFIRINOX. The opposite trend was seen in patients with other KRAS variants including G12D, G12V…
DOI:
10.1200/JCO.2023.41.16_suppl.4150
